Investors applaud Schein's record sales and earnings

Shares of distributor Henry Schein ($HSIC) were up more than 6% to $156.91 in morning trading on February 10, after the company announced record fourth-quarter and full-year results. Schein's net sales for the quarter were up 5% year over year to $2.9 billion, while its adjusted net income grew 7% to $139.3 million ($1.67 per share). Sales in the company's animal health division rose 3% to $756.2 million. For the full year, Schein chalked up sales of $10.6 billion, up 2.5% from 2014, and adjusted net income of $501.5 million or $5.96 per share, which was almost a 10% improvement from the previous year. CEO Stanley Bergman noted in the earnings release that he expects Schein to get a further boost from its recent acquisitions of health analytics company Vetstreet and practice-management software maker RxWorks. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…